Nail detachment over four times more common among GLP-1 users, first controlled study finds
4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Evidence dossier
Intelligence passport
Measured timeline
What happened
- Velocity & Diffusion: Coverage exploded across 4 distinct news outlets with 4 published articles, achieving a live velocity of 2.
- Primary Driver: 4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
- Source Integrity: Verified strictly against primary headline reporting under zero-hallucination protocols.
"Nail detachment over four times more common among GLP-1 users, first controlled study finds" is generating significant coverage in the Health category, with 4 articles from 4 distinct sources tracked by Archynetys so far.
Outlets currently covering the story include inc.com, thepharmacist.co.uk, Everyday Health and U.S. News & World Report. Archynetys measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
Synthesized from multi-source international reporting and live coverage telemetry under Archynetys open intelligence methodology.
Generated by Archynetys's extractive engine from coverage metadata only — no AI-written claims. Updated 2h ago.
Coverage (4)
-
-
GLP-1 drug users report more nail and hair problems, study findsthepharmacist.co.uk · 1d ago
-
GLP-1 Drug Effects on Hair, Skin, and NailsEveryday Health · 1d ago
-
Odds Of Losing Your Nails, Hair Rise With GLP-1 UseU.S. News & World Report · 1d ago
Questions people are asking
Why is "Nail detachment over four times more common among GLP-1 users, first controlled " trending?
Because 4 independent news sources published 4 articles about it in a short window — a coverage burst Archynetys classifies as a trend.
How does Archynetys measure this trend?
Archynetys scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
How do you expect this trend to evolve over the next 24 hours?
Cast your vote to register reader intelligence on the velocity and trajectory of this coverage.
Topics
Related trends
Rapid weight loss on popular drugs could ‘starve’ the brain, expert warns
7 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Dad claims he went suddenly, permanently blind from Ozempic — in one of hundreds of lawsuits against GLP-1 makers
A wave of lawsuits alleging permanent blindness from Ozempic fuels new medical warnings and risk‑assessment tests.
Navigating GLP-1 Switches: A Guide for Primary Care
4 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
Once described as obesity medicines for 'patients,' GLP-1s are increasingly lifestyle drugs for 'customers'
GLP-1s shift from 'patients' to 'customers' as weight loss trend surges
Does GLP-1 use result in significant hair loss?
11 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
GLP-1 lawsuit: Patient’s attorney describes life-changing effects from taking drug
4 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
Open prediction lab
Can you beat the machine?
Pick tomorrow's top trend, then compare your result with Archynetys's self-graded forecast.
📬 The daily trend digest
The world's top trends, once a day. No spam, one-click unsubscribe.